文献速递心脏核医学

心肌灌注显像的PET与SPECT示踪剂

PET and SPECT Tracers for Myocardial Perfusion Imaging.
PubMed 文献 · Semin Nucl Med · 2020-03-13

本文综述了心肌灌注显像(MPI)用PET与SPECT示踪剂的研发现状与发展趋势,涵盖已临床可用及在研中潜力最大的示踪剂。文章指出PET MPI因图像质量更优而诊断准确性优于SPECT,动态PET可定量心肌血流量(MBF)与心肌血流储备(MFR),并讨论了专用SPECT扫描仪开展动态成像与MBF定量的研究进展。

要点

  • PET MPI图像质量优于SPECT,诊断准确性更高
  • 动态PET可定量MBF与MFR,在MPI基础上进一步提升诊断与预后准确性
  • 专用心脏SPECT扫描仪可动态成像,激发SPECT示踪剂MBF定量研究

核心结论

  • 由于对相关生理学理解更深入、化学工具更优及小动物成像的发展,灌注放射性示踪剂研发速度加快。
  • 条件不断演变,既往被认为较差的示踪剂可能被重新考虑用于未来应用,而部分新近开发的示踪剂可能并非最优。

研究设计与样本

  • 综述:回顾当前临床可用及在研中潜力最大的心肌灌注示踪剂。
  • 对每种示踪剂讨论研发理由、心肌摄取的生理机制、已发表的评价结果与研发现状。
  • 评估每种示踪剂用于临床应用的适宜性。

主要发现

  • 冠状动脉疾病自20世纪60年代以来一直是主要死因,推动了MPI药物的研发。
  • SPECT MPI一直是临床主力,但过去二十年来PET MPI因图像质量提升而增长,诊断准确性优于SPECT。
  • 动态PET成像可常规以绝对单位定量MBF与MFR,并在MPI基础上增量改善诊断与预后准确性。
  • 在某些情况下(如铷PET显像配合药物负荷),MPI、MBF与MFR可同时采集,不增加成本、辐射暴露或显著处理时间。
  • 传统SPECT与MPI示踪剂不足以应对MBF定量挑战,专用心脏SPECT扫描仪可动态成像并推动SPECT示踪剂MBF定量研究。

关键数值与推荐

  • 新灌注示踪剂须针对新兴临床需求(包括MBF定量)、成像设备技术能力、市场约束与供应链可行性进行定制。

临床怎么用

  • 核心脏科诊所一直希望将MBF定量纳入临床常规,但传统SPECT与MPI示踪剂不足以应对这一挑战。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery disease has been the leading cause of death since the 1960s, which has motivated the research and development of myocardial perfusion imaging (MPI) agents for early diagnosis and to guide treatment. MPI with SPECT has been the clinical workhorse for MPI, but over the past two decades PET MPI is experiencing growth due to enhanced image quality that results in superior diagnostic accuracy over SPECT. Furthermore, dynamic PET imaging of the tracer distribution process from time of tracer administration to tracer accumulation in the myocardium has enabled routine quantification of myocardial blood flow (MBF) and myocardial flow reserve (MFR) in absolute units. MBF and MFR incrementally improve diagnostic and prognostic accuracy over MPI alone. In some cases (eg, rubidium PET imaging with pharmacologic stress) MPI, MBF, and MFR can be acquired simultaneously without incremental cost, radiation exposure, or significant processing time. Nuclear cardiology clinics have been looking to incorporate MBF quantification into clinical routine, but traditional SPECT and MPI tracers are inadequate for this challenge. Cardiac dedicated SPECT scanners can also perform dynamic imaging and have stimulated research into MBF quantification using SPECT tracers. New perfusion tracers must be tailored for emerging clinical needs (including MBF quantification), technical capabilities of imaging instrumentation, market constraints, and supply chain feasibility. Because these conditions have been evolving, tracers previously considered inferior may be reconsidered for future applications and some recently developed tracers may be suboptimal. This article reviews current, clinically-available tracers and those under development showing greatest potential. It discusses for each tracer the rationale for development, physiological mechanism of uptake by the myocardium, published evaluation results and development state. Finally, it gauges the suitability of each tracer for clinical application. The article demonstrates an acceleration in the pace of perfusion radiotracer development due to better understanding of the relevant physiology, better chemistry tools and small animal imaging. Consequently, bad tracers may fail faster and with less wasted investment, and good tracers may translate more efficiently from bench to bedside.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Klein R, Celiker-Guler E, Rotstein BH, et al. PET and SPECT Tracers for Myocardial Perfusion Imaging. Semin Nucl Med. 2020. PMID: 32284107. doi:10.1053/j.semnuclmed.2020.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。